Poor prognosis of intra-tumoural TRBV6-6 variants in EGFR-mutant NSCLC: Results from the ADJUVANT-CTONG1104 trial

Clin Transl Med. 2022 Apr;12(4):e775. doi: 10.1002/ctm2.775.

Cunte Chen¹, Siyang Maggie Liu^{1

2

3}, Yedan Chen⁴, Ming Han⁴, Qiuxiang Ou⁴, Hua Bao⁴, Ling Xu¹, Yikai Zhang¹, Jia-Tao Zhang⁵, Wenzhao Zhong⁵, Qing Zhou⁵, Xue-Ning Yang⁵, Yang Shao^{4

6}, Yi-Long Wu⁵, Si-Yang Liu⁵, Yangqiu Li¹

¹ Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, China.
² Department of Hematology, First Affiliated Hospital, The Clinical Medicine Postdoctoral Research Station, Jinan University, Guangzhou, China.
³ Chinese Thoracic Oncology Group (CTONG), Guangzhou, China.
⁴ Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China.
⁵ Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangdong Lung Cancer Institute, Guangzhou, China.
⁶ School of Public Health, Nanjing Medical University, Nanjing, China.

No abstract available

Publication types